Mizuho sees black box warning just for Bluebird, not Crispr

Mizuho analyst Salim Syed keeps a Buy rating on Crispr Therapeutics (blue‘>CRSP) with an $82 price target after Bluebird Bio (BLUE) received FDA approval for Lyfgenia for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events. The firm anticipates a “relatively clean label” for Crispr’s and Vertex’s (VRTX) Casgevy and interprets the black box warning from the FDA statement as just for the Bluebird product.